Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Katarzyna Roszek
The numerous subpopulations of plasma lipoproteins, each of which has a distinct number and size of particles, are not adequately represented by the standard lipid panel. In order to determine whether certain lipoprotein subpopulations are associated with insulin resistance and inflammation markers, we sought to quantify lipoprotein subpopulations in patients with type 2 diabetes mellitus (T2DM). 57 T2DM patients ranging in age from 61.14 to 9.99 years were included in the study; HbA1c, 8.66 ± 1.60%; on average, BMI of 35.15 minus 6.65 kg/m2). Nuclear magnetic resonance spectroscopy was used to determine the size and count of plasma lipoprotein particles. Multiregression analysis was used to investigate the connection between scores for glycoprotein acetylation (GlycA) and lipoprotein insulin resistance (LPIR). The largest numbers and sizes of VLDL and HDL particles were found to be most correlated with LPIR in stepwise regression analysis (R2 = 0.960; However, there was a correlation between HDL and VLDL particle concentrations and GlycA (R2 = 0.190; All sizes of lipoproteins, as well as small and large VLDL particles, independently predicted LPIR in adjusted multi-regression analysis (p = 0.0001), whereas only a small number of LDL particles independently predicted GlycA. Conventional markers HbA1c and Hs-CRP did not have a significant relationship with lipoprotein subpopulations. Based on our findings, we hypothesize that by keeping an eye on the changes caused by insulin resistance in T2DM subpopulations of lipoproteins, we might be able to find novel biomarkers that could be used in clinical intervention.